Colorectal cancer has become the third most common cancer worldwide, following lung and breast cancers, and its incidence continues to rise globally. Amid growing concerns about increasing cases—especially among younger adults—new developments in immunotherapy are offering hope for a subset of patients with specific genetic profiles.

Recent clinical studies in the United States have revealed promising outcomes where some rectal cancer patients experienced complete disappearance of tumors after receiving immunotherapy treatments. These responses are particularly seen in patients whose tumors carry certain molecular characteristics, often linked to Lynch syndrome, an inherited genetic condition that significantly increases the risk of cancers such as colorectal, endometrial and ovarian cancer.

Individuals with Lynch syndrome often develop cancer at a younger age, typically in their 40s or 50s. For these patients, immunotherapy drugs that activate the body’s immune system to attack cancer cells are showing extraordinary potential.

Immune checkpoint inhibitors such as nivolumab and ipilimumab, which were approved by the US Food and Drug Administration (FDA), are being used together in certain cases. Another drug, dostarlimab, has also demonstrated remarkable results in patients with rectal cancers carrying the right genetic markers.

According to medical experts, these therapies work by enabling the immune system to recognize and destroy cancer cells more effectively. In some cases, patients have shown no detectable signs of cancer after just a few months of treatment.

Clinical trial data has further strengthened optimism around these therapies. In one study, patients receiving the combination of nivolumab and ipilimumab experienced a dramatic improvement in progression-free survival, increasing from about 5.9 months with traditional chemotherapy to more than 54 months.

Another widely discussed study conducted at Memorial Sloan Kettering Cancer Center in New York reported a complete clinical response in all 12 patients with locally advanced rectal cancer treated with dostarlimab. After treatment, scans and medical examinations found no evidence of cancer in any participant.

Although researchers stress that larger studies are still needed, the results have generated cautious optimism in the oncology community. Immunotherapy may not work for every colorectal cancer patient, but for those with specific genetic markers, it could significantly reduce the need for surgery, chemotherapy and radiation.

As research continues, experts believe immunotherapy could reshape the future of rectal cancer treatment—potentially offering less invasive care and better long-term outcomes for many patients.